A consolidated talc case involving three women who died from ovarian cancer, concluded with a 10-2 defense verdict for Johnson & Johnson on June 5, 2026, in Los Angeles Superior Court. That result follows a $40 million plaintiff win in California in December 2025 and reflects a troubling pattern of corporate defendants disrupting plaintiff infrastructure while going after causation evidence through expert exclusions and ethics disqualifications.
The consolidated case involved the families of Mary Owens, Bonnie Tienken, and Geneva Williams, who alleged that J&J's cosmetic talc products were contaminated with asbestos and caused their terminal ovarian cancer.
Plaintiff counsel sought punitive damages and argued in closing arguments that J&J put profits ahead of consumer safety. The jury found no negligence, with plaintiff attorney Ari Friedman calling the outcome deeply disappointing.
J&J denied everything, saying its products were perfectly safe and contained no asbestos at all. Its victory was based on tough pretrial tactics against expert witnesses. By heavily leaning on prior federal rulings that excluded key plaintiff expert testimony for not being scientifically sound, the defense created overwhelming doubt. J&J's Vice President of Litigation immediately took to the press to label the plaintiffs' entire case as based on junk science.
The expert exclusion strategy
J&J deployed aggressive Daubert and Sargon challenges to exclude plaintiff causation experts before trial. Because juries did not hear from certain excluded experts who could draw a definitive line between talc use and ovarian cancer, J&J won the battle of the experts.
The defense utilized macro-level epidemiological frameworks focusing on occupational worker cohorts and aggregate consumer registries that deliberately induce a narrative of statistical ambiguity. These population-based studies are focused toward male occupational groups and do not address specific low-incidence transdermal perineal migration pathways relevant to ovarian cancer claims.
Competing expert dockets created structural imbalances in how causation data was vetted, and the defense benefited from it. When plaintiff experts can't get past Daubert challenges to explain the mechanism linking talc to ovarian cancer, juries have little choice but to absorb the defense's narrative. Firms that don't protect their experts from exclusion risk losing trials before they really start.
The ethics weapon: Beasley Allen disqualification
To understand this defense verdict, the strategic disruption J&J orchestrated against plaintiff leadership must be examined. In late March 2026, a federal magistrate judge disqualified Beasley Allen from serving as co-lead counsel in the federal MDL. This mirrored a February 2026 New Jersey state court ruling that removed the firm from over 3,600 state cases.
J&J successfully argued that an ethical breach occurred because Beasley Allen collaborated on a $19 billion settlement strategy with James Conlan, a former defense attorney who had previously billed over 1,600 hours defending J&J in talc litigation. Beasley Allen was the primary roadblock that defeated J&J's earlier attempts to offload liabilities into bankruptcy court.
Disqualifying them forced roughly 5,500 federal MDL plaintiffs and 3,600 state plaintiffs to seek new counsel. David Selby of Bailey & Glasser noted this ouster had a devastating impact by intentionally delaying trials, scrambling resources, and removing top-tier institutional knowledge from plaintiff ranks.
Strategic impact on remaining inventory
While the Los Angeles result stings, J&J's trial record overall is still mixed, and the $40 million California verdict from late 2025 keeps things in balance. With talc-based powder off the US market since 2020, J&J's entire focus is on managing what it's already left behind. The defense strategy for the remaining trials has become clear. Plaintiff firms need to be ready for three coordinated tactics:
- Expert witness weaponization: Daubert challenges are a primary J&J weapon aimed at eliminating plaintiff causation experts. A scientific narrative that can't withstand that pressure leaves juries defaulting to junk science from the defense.
- Leadership disruption: The defense actively searches for ethical or procedural hooks to take plaintiff counsel out of the picture. Strict operational hygiene is essential, as is not relying only on the MDL steering committee momentum.
- Attrition warfare: J&J prefers individual trials to consolidated trials and uses the financial drain of constant preparation and scheduling delays to bleed plaintiff firms dry.
Atraxia Media provides expert witness intelligence
Corporate defendants are systematically using expert preemption across the remaining dockets, making witness intelligence a critical part of trial preparation. Atraxia Media keeps detailed rosters of admitted and excluded expert witnesses, covering the technical anchors and tactical vulnerabilities that have been targeted during cross-examination.
If your firm holds ovarian cancer talc cases, contact Atraxia Media to discuss how we provide expert witness intelligence that insulates your causation architecture from exclusion and effectively dismantles the defense's aggregate statistics narrative.